scout
|Videos|July 13, 2017

Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Bekaii-Saab says the big takeaways from the phase II study of napabucasin with gemcitabine and nab-paclitaxel is that it is a safe regimen, and given the lack of standard of care in pancreatic cancer, this is an opportunity to improve upon the activity of an established regimen.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME